首页
>
>
投稿咨询
微信添加科研助理

了解相关问题

加急服务
微信添加科研助理

了解相关问题

CARDIOVASCULAR DRUGS AND THERAPY
ISSN：0920-3206

CARDIOVASCULAR DRUGS AND THERAPY

CARDIOVASC DRUG THER
学科领域：医学
是否预警：不在预警名单内
是否OA：否
录用周期：平均4.5月
新锐分区：医学3区
年发文量：86
影响因子：3.1
JCR分区：Q2

基本信息

《心血管药物与治疗》旨在客观地涵盖心血管药物、设备和细胞治疗从实验室到临床的发展过程，并以及时和有用的形式为您提供您最需要的信息，以新鲜和充满活力的眼光看待这一动态领域的进展。高脂血症、糖尿病、局部缺血综合征和心律失常。期刊是当前和相关信息的权威来源，对于致力于创新、突破性研究的基础和临床研究者以及寻求最佳患者服务的心脏病专家来说，是不可或缺的。为您提供公认为世界上最好的单一、简洁的参考工具。心血管药物和治疗在Web of Science和PubMed/Medline以及其他摘要和索引服务中列出。定期的文章和经常性的专题问题为您提供了一个最新的来源，定义为对一个不断发展的领域的准确信息的需要。心血管药物和治疗是一个仔细和准确的指南，通过迷宫的新产品和治疗，为您提供了详细的心血管药理学，您将参考一次又一次。
0920-3206SCIE/Scopus收录
3.1
点击查看最新影响趋势>
3.4
新
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学3区
CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统
3区
PHARMACOLOGY & PHARMACY 药学
3区
否
N/A
新
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科：CARDIAC & CARDIOVASCULAR SYSTEMS
SCIE
Q2
70/231
学科：PHARMACOLOGY & PHARMACY
SCIE
Q2
134/352
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科：CARDIAC & CARDIOVASCULAR SYSTEMS
SCIE
Q2
72/231
学科：PHARMACOLOGY & PHARMACY
SCIE
Q2
127/353
63
86
点击查看年发文量趋势图>
14%约67.5%平均4.5月-医学-心血管系统
6.5%
点击查看自引率趋势图>
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
63.95%27.55%-
CiteScore：9.00
SJR：1.002
SNIP：0.997
学科类别分区排名百分位
大类：Medicine
小类：Pharmacology (medical)
Q1
28 / 275
大类：Medicine
小类：Cardiology and Cardiovascular Medicine
Q1
46 / 397
大类：Medicine
小类：Pharmacology
Q1
47 / 321

期刊高被引文献

Dexmedetomidine Preconditioning Protects Cardiomyocytes Against Hypoxia/Reoxygenation-Induced Necroptosis by Inhibiting HMGB1-Mediated Inflammation
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06857-1
“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06873-1
The Role of Thyroid Hormones in Heart Failure
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06870-4
Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06892-y
Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06901-0
Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06851-7
Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06907-8
The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06914-9
Activation of T Lymphocytes as a Novel Mechanism in Beta1-Adrenergic Receptor Autoantibody-Induced Cardiac Remodeling
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06856-2
State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06904-x
Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06910-z
Absence of Functional Nav1.8 Channels in Non-diseased Atrial and Ventricular Cardiomyocytes
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06925-6
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06852-6
Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06911-y
Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06864-2
Impact of Ca2+-Sensitive Potassium Channels in Levosimendan-Induced Postconditioning
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06908-7
Cardioprotective Effects of Beta3-Adrenergic Receptor (β3-AR) Pre-, Per-, and Post-treatment in Ischemia–Reperfusion
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06861-5
LncRNA MALAT1 Promotes Oxygen-Glucose Deprivation and Reoxygenation Induced Cardiomyocytes Injury Through Sponging miR-20b to Enhance beclin1-Mediated Autophagy
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06902-z
Platelet MicroRNA 365-3p Expression Correlates with High On-treatment Platelet Reactivity in Coronary Artery Disease Patients
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06855-3
The Effect of Ranolazine on Glycemic Control: a Narrative Review to Define the Target Population
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06917-6
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06906-9
Attainment of Guideline-Directed Medical Treatment in Stable Ischemic Heart Disease Patients With and Without Chronic Kidney Disease
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06883-z
Resolvin D1 Attenuates Myocardial Infarction in a Rodent Model with the Participation of the HMGB1 Pathway
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06884-y
Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06885-x
Omitting aspirin in PCI patients: Myth or reality?
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06916-7
Activation of T Lymphocytes as a Novel Mechanism in Beta1-Adrenergic Receptor Autoantibody-Induced Cardiac Remodeling—Additional Information About TLR9 Involvement
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06874-0
Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06898-6
HDL-Targeted Therapies During Myocardial Infarction
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06865-1
Effects of PDE-5 Inhibition on the Cardiopulmonary System After 2 or 4 Weeks of Chronic Hypoxia
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06887-9
Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores Vascular Reactivity Through a Perivascular Adipose Tissue-Independent Mechanism in Rats with Metabolic Syndrome
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06900-1
Long-Term Efficacy and Safety of Immunomodulatory Therapy for Atherosclerosis
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06890-0
After the AUGUSTUS Trial, Should Apixaban Be the Only Direct Oral Anticoagulant to Be Used in Triple Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention?
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06886-w
Five-Year Outcomes of Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Durable Polymer Drug-Eluting Stents: a Meta-Analysis of Randomized Controlled Trials
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06912-x
Association of Elevated Plasma Homocysteine Level with Restenosis and Clinical Outcomes After Percutaneous Coronary Interventions: a Systemic Review and Meta-analysis
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06866-0
A Novel Epigenetic Drug-Eluting Balloon Angioplasty Device: Evaluation in a Large Animal Model of Neointimal Hyperplasia
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06921-w
Inhibition of Niemann-Pick C1-Like 1 by Ezetimibe Reduces Dietary 5β,6β-Epoxycholesterol Absorption in Rats
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06854-4
My Last Issue—a Farewell to Cardiovascular Drugs and Therapy
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06928-3
Efficacy of Antiplatelet Agent Usage for Primary and Secondary Prevention in Dialysis Patients: a Nationwide Data Survey and Propensity Analysis
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06882-0
Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06913-w
Plasma from Volunteers Breathing Helium Reduces Hypoxia-Induced Cell Damage in Human Endothelial Cells—Mechanisms of Remote Protection Against Hypoxia by Helium
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06880-2
Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06872-2
HFREF Patients and Atrial Fibrillation: Time to Reconsider the Appropriateness of the Atrial Fibrillation Ablation in This Patient Subset?
来源期刊：Cardiovascular drugs and therapyDOI：10.1007/s10557-019-06881-1
Fibrinolysis: a Misunderstood Natural Defense Whose Therapeutic Potential Is Unknown
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06923-8
Medical Misinformation: Vet the Message!
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06859-z
Association of Regulatory Genetic Variants for Protein Kinase Cα with Mortality and Drug Efficacy in Patients with Heart Failure
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06909-6
Chewed or Crushed Administration of Adenosine Diphosphate Receptor Inhibitors in Acute Coronary Syndromes: a Systematic Review and Meta-analysis of Randomized Controlled Trials
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06905-w
Special Issue: British Society for Cardiovascular Research
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06877-x
Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06920-x
From the Choice of a Regimen to the Choice of an Intensity: Changing Perspective in the Antithrombotic Therapy of Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06903-y

相关文章

Materials Today Bio解析：IF=8.7，8天初审
2025-11-25
《ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE》德国老牌产科期刊免版面费、非预警，毕业保底首选！
2025-11-25
Journal of Multidisciplinary Healthcare：IF= 2.4，中科院3区，JCR Q2，多学科综合医学开放获取期刊，应用性强，审稿迅速，编辑反馈专业！
2025-10-15
European Journal of Medical Genetics：IF= 1.7，中科院4区，JCR Q3，医学遗传学期刊，涵盖分子遗传学、临床基因诊断与罕见病研究，欧洲地区影响力较稳，国际传播适中！
2025-10-15
ANNALS OF ONCOLOGY：中科院1区，肿瘤学，接受率为25%
2025-10-15
Journal of Cystic Fibrosis：权威官方背景，高影响力，整体周期约 3 个月，部分 1 天录用
2025-10-15
JOURNAL OF INHERITED METABOLIC DISEASE：影响因子平稳，学术认可度高，年发文稳定，4个月录用
2025-10-15
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE：自引风险小，审稿周期短，发表难度低，但if持续下降
2025-10-15
Neurobiology of Stress：中科院 2 区，认可度高，国人发文第二，机会公平
2025-10-15
NATURE REVIEWS DRUG DISCOVERY：中科院1区，生物工程与应用微生物，药学，接受率为21%
2025-10-15

期刊推荐

AAPS Journal封面

AAPS Journal

学科领域：医学
影响因子：3.7
中科院分区： 3区
AAPS PHARMSCITECH封面

AAPS PHARMSCITECH

学科领域：医学
影响因子：4
中科院分区： 3区
Academic Pediatrics封面

Academic Pediatrics

学科领域：医学
影响因子：2.8
中科院分区： 3区
ACTA ANAESTHESIOLOGICA SCANDINAVICA封面

ACTA ANAESTHESIOLOGICA SCANDINAVICA

学科领域：医学
影响因子：2
中科院分区： 3区
论文发表 2-4个月录用 7500+文章录用 不成功可退款
新
2026年3月发布（新锐分区）
大类学科小类学科Top期刊综述期刊
医学3区
CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统
3区
PHARMACOLOGY & PHARMACY 药学
3区
否
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学3区
PHARMACOLOGY & PHARMACY 药学
3区
CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统
4区
否
否
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学3区
PHARMACOLOGY & PHARMACY 药学
3区
CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统
4区
否
否